Prime Medicine Inc (NASDAQ:PRME) traded at $4.86 at close of the session on Monday, April 29, made an upward move of 9.83% on its previous day’s price.
Looking at the stock we see that its previous close was $4.43. In terms of its 52-week price range, PRME has a high of $17.20 and a low of $4.11. The company’s stock has lost about -30.57% over that past 30 days.
Prime Medicine Inc has a market cap of $582.91 million. Estimates by analysts give the company expected earnings per share (EPS) of -$0.47, with the EPS growth for the year raised at -$1.83 for 2024 and -$1.64 for next year. These figures represent 16.10% and 10.40% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $910k, with a high of $6 million.
On the other hand, looking at the outlook for the PRME stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of 100% Sell. Long term indicators on average place the stock in the category of 100% Sell.
Looking further, we note the current price level is -9.90% off its SMA20 and -29.42% from its 50-day simple moving average. The RSI (14) is pointing at 37.92 while the volatility over the past week is 10.03% and jumps to 7.75% over the past one month. The beta value is 2.16, while the average true range (ATR) is currently pointing at 0.47.
Coming back to Prime Medicine Inc (NASDAQ:PRME), we note that the average 3-month trading volume was 729.13K. Current shares outstanding are 97.38 million.
The insiders hold 58.50% of the company’s shares while institutions hold 27.56%. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -45.15% down in year-to-date price movement.
